First-of-its kind clinical trial led by scientists at UCL and the University of Sheffield, and funded by The Urology Foundation and the Champniss Foundation
A new study, published in JAMA, has found that robotic surgery reduces the chance of readmission by half (52 per cent), and revealed a “striking” four-fold (77 per cent) reduction in prevalence of blood clots (deep vein thrombus and pulmonary emboli) – a significant cause of health decline and morbidity – when compared to patients who had open surgery.
Patients’ physical activity assessed by daily steps tracked on a wearable smart sensor – stamina and quality of life also increased.
Researchers say the findings provide the strongest evidence so far of the patient benefit of robot-assisted surgery and are now urging National Institute of Clinical Excellence (NICE) to make it available as a clinical option across the UK for all major abdominal surgeries including colorectal, gastro-intestinal, and gynaecological.
Co-Chief Investigator Professor James Catto, Professor of Urological Surgery at the University of Sheffield’s Department of Oncology and Metabolism, said: “This is an important finding. Time in hospital is reduced and recovery is faster when using this advanced surgery. Ultimately, this will reduce bed pressures on the NHS and allow patients to return home more quickly. We see fewer complications from the improved mobility and less time spent in bed.”
“The study also points to future trends in healthcare. Soon, we may be able to monitor recovery after discharge, to find those developing problems. It is possible that tracking walking levels would highlight those who need a district nurse visit or perhaps a check-up sooner in the hospital. Previous trials of robotic surgery have focused on longer term outcomes. They have shown similar cancer cure rates and similar levels of long term recovery after surgery. None have looked at differences in the immediate days and weeks after surgery.”
Co-Chief Investigator, Professor John Kelly, Professor of Uro-Oncology at UCL’s Division of Surgery & Interventional Science & consultant surgeon at University College London Hospitals Trust, said: “Despite robot-assisted surgery becoming more widely available, there has been no significant clinical evaluation of its overall benefit to patients’ recovery.
“In this study we wanted to establish if robot-assisted surgery, when compared to open surgery reduced time spent in hospital, reduced readmissions, and led to better levels of fitness and a quality of life; on all counts this was shown. An unexpected finding was the striking reduction in blood clots in patients receiving robotic surgery; this indicates a safe surgery with patients benefiting from far less complications, early mobilisation and a quicker return to normal life.”
Professor Kelly added: “In light of the positive findings, the perception of open surgery as the gold standard for major surgeries is now being challenged for the first time. We hope that all eligible patients needing major abdominal operations can now be offered the option of having robotic surgery.”
Rebecca Porta, CEO of The Urology Foundation said, “We are proud to have been at the heart of the step change in the treatment and care for urology patients since our inception 27 years ago, and the outcomes of this trial will improve bladder cancer patients’ treatment and care. The funding of this important study was made possible through a generous grant from the Champniss Foundation.”
The research team is conducting a health economic analysis to establish the quality-adjusted life year (QALY), which incorporates the impact on both the quantity and quality of life.
- Advertisement -